SVRA stock touches 52-week low at $1.91 amid market challenges

Savara Inc. (SVRA) stock has reached a 52-week low, dipping to $1.91, as the company faces a challenging market environment. According to InvestingPro data, while the company maintains a strong current ratio of 14.91 and holds more cash than debt, it’s quickly burning through its cash reserves. Over the past year, the stock has experienced a significant downturn, with Mast Therapeutics (NASDAQ:SVRA), now part of Savara, witnessing a 1-year change of -31.57%. This decline reflects broader market trends and investor sentiment, as the company navigates through a period of volatility and strategic repositioning. Analysts maintain a bullish outlook, with price targets ranging from $3 to $16. Investors are closely monitoring the stock’s performance for signs of a turnaround or further decline as the market continues to evolve. Get deeper insights and 8 additional key ProTips with InvestingPro’s comprehensive analysis.

In other recent news, Savara Inc. has encountered a regulatory challenge as the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for the company’s Biologics License Application (BLA) for MOLBREEVI. The FDA’s review highlighted a lack of completeness in the Chemistry, Manufacturing, and Controls data section, though no safety concerns were noted. Savara plans to address these issues and resubmit the BLA later in 2025. Meanwhile, JMP Securities has reiterated its Market Outperform rating for Savara with a $10 price target, expressing optimism about the potential acceptance of the BLA and a Priority Review due to MOLBREEVI’s Breakthrough Therapy designation.

Additionally, Savara is preparing to present data from a recent Phase 3 clinical trial for molgramostim, another treatment for autoimmune pulmonary alveolar proteinosis, at medical congresses in Germany and Japan. In a strategic move, Savara also announced the termination of its sales agreement with Evercore Group for the sale of common stock, which had been in place since 2021. H.C. Wainwright has maintained a Buy rating with a $6 price target for Savara, highlighting the potential for MOLBREEVI to become the first approved therapy for autoimmune pulmonary alveolar proteinosis. Analysts emphasize the importance of accurate diagnosis facilitated by the aPAP ClearPath blood test for the successful launch of MOLBREEVI.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.